Cancer Education
focusing on Specialized Topics of Interest

Taught by the Experts




www.BMLI.com

Symposium Co-Chairs

Paul A Bunn Jr MD
Paul A. Bunn, Jr., MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO
H. Jack West, MD
H. Jack West, MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education (GRACE)
Seattle, WA

Medical Oncology Faculty

Tracey L. Evans, MD
Tracey L. Evans, MD
Associate Professor of Clinical Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Edward B. Garon, MD
Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
Jonathan Goldman, MD
Jonathan Goldman, MD
Associate Professor of Medicine
Lung Cancer Research
Department of Hematology/Oncology
UCLA Ronald Reagan Medical Center
Santa Monica, CA
Richard J. Gralla, MD, FACP
Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
Fred R. Hirsch, MD, PhD
Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director, University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Denver, CO
Ronald B. Natale, MD
Ronald B. Natale, MD
Director of the Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Joel Neal, MD, PhD
Joel Neal, MD, PhD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA
David R. Spigel, MD
David R. Spigel, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN
Heather A. Wakelee, MD
Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford Comprehensive Cancer Center
Stanford, CA

Oncology Nursing Faculty

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Clinical Instructor in Nursing
Thoracic Oncology Program
Yale Comprehensive Cancer Center
Yale Schools of Nursing and Medicine
New Haven, CT

Oncology Pharmacist Faculty

Jim M. Koeller, MS
Jim M. Koeller, MS
Professor,
University of Texas at Austin
College of Pharmacy,
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine, Pharmacotherapy Education & Research
University of Texas Health Science Center at San Antonio
San Antonio, TX

An opportunity to visit San Francisco at a very low price of $162 a night while attending a highly informative symposium.

Agenda

Back to Top

7:00AM Registration and Full Buffet Breakfast
8:00AM Welcome, Introductions and CME/CE Pre Test
Paul A. Bunn, Jr., MD
SESSION #1: The Continuing Evolution of Immune Therapy for Non-Small Cell Lung Cancer
Chair: Paul A. Bunn, Jr., MD
8:10AM Rapid-Fire "Yes/No" questions to engage the audience
  • All immuno-oncology therapies are the same and interchangeable. Yes? No?
  • Many payers in my geographical area are reimbursing for use of immune therapy for lung cancer in the 1st-line setting. Strongly Agree Agree, Unsure, Disagree, Strongly Disagree.
  • When patients request it I attempt to get authorization to use immune therapy in 1st line? Yes? No?
  • There is a standard, optimal chemotherapy backbone to be used with immune-therapy. Yes? No?
  • Combinations of dual immune-therapy are likely to be more effective than monotherapy Yes? No?
Paul A. Bunn, Jr., MD
8:20AM DEBATE 1: Checkpoint inhibition for refractory NSCLC, with or without testing for PD-L1
  • NSCLC patients should receive a PD-1 inhibitor in the second-line setting without being tested for PD-L1 expression. (Spigel)
  • NSCLC patients should be tested for PD-L1, and if this expression is positive, then the checkpoint inhibitor with this FDA labeling requirement should be used preferentially versus the other checkpoint inhibitor without this testing requirement. (Garon)
D. Spigel versus E. Garon
8:40AM Combination Immune-therapy for refractory NSCLC:
  • What are the clinical applications for dual immune-oncology therapy?
  • What are the clinical applications of combinations of immune-oncology therapy plus either targeted therapy or plus chemotherapy?
  • What are the clinical applications of sequential use of these strategies?
  • Is there a standard chemotherapy for use in combination with immune therapy?
D. Spigel
9:00AM Expert Panel Discussion and Q&A -- The potential clinical applications of immune-therapy in treatment-naïve NSCLC: An Expert Panel Discussion of Drs. Bunn, Spigel and Garon et al
  • If immune therapy is either FDA approved or reimbursed for first-line use, for which patients should it be considered as an option?
  • Is first-line therapy going to become a standard of care? If standard, will it be as a single agent or in combination regimens?
  • What are the clinical roles for immune therapy in patients with an actionable mutation?
  • Are some payers reimbursing for first-line usage?
P. Bunn & Session #1 Faculty
9:30AM Audience Q & A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones for Session #1
P. Bunn & Session #1 Faculty
SESSION #2: New Diagnostics for New and Emerging Targets Receiving NSCLC Therapy
Chair: H. Jack West
9:40AM DEBATE #2: Plasma–based Next Generation Sequencing (NGS) liquid biopsy testing is sufficiently reliable and cost-effective to be used routinely in advanced NSCLC to identify actionable mutations.
  • YES: J. Neal
  • NO: H. Jack West
J. Neal vs. H. West
10:00AM BREAK
10:20AM Genetic profiles in younger NSCLC patients: Should younger patients receive Next Generation Sequencing (NGS) Testing any differently than older adults?
E. Garon
10:40AM Implications of NGS testing on therapy selection:
  • Is the treatment of NSCLC patients with mutations such as KRAS, CDK4, CDK6, BRAF, HER2, RET, MET, MEK, ROS1, and are areas such as T-cells and stem cells becoming a realistic option with commercially available therapies in the absence of FDA-approved indications?
  • What about testing and clinical trials for KRAS which has a greater prevalence than EGFR?
J. Goldman
11:00AM Expert Panel Discussion and Q&A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones, for Session #2
H. Jack West & Session 2 faculty
SESSION #3: The Increasing Importance of Value-Based Care for Lung Cancer
Chair: T. Evans
11:10AM Value-Based Care: What does a cancer Health Care Professional (HCP) Need to Know? What is meant by value-based cancer care? What are the current strategies that are being used to establish this versus fee for service?
  • How is value defined?
  • How do we transition from fee for service to a value-based system?
  • The “Come Home Project” CMMI
J. Koeller
11:30AM How Appropriate Therapeutic and Supportive Care Helps Appropriate Patient Care in the Value Proposition: Defining the benefits
T. Evans
11:50AM Expert Panel Discussion and Q&A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones, for loss of appetite and weight and also for current and emerging interventions
T. Evans & Session 3 faculty
NOON
LUNCH Options: CME/CE is provided
  • LUNCH WITH THE PROFESSORS (for all attendees)
    All faculty
  • Pharmacists: An In-Depth Role of Cancer Therapy Value.
    Jim Koeller
  • Nurses: The Rise of the Patient in Cancer Therapy Value and Therapy Selection: How can the oncology nurse enhance this?
    Marianne Davies
1:00PM The increasingly critical role of supportive care in the improvement in NSCLC patient outcomes and therapy value: And the increasing role of patient reported outcomes as clinical endpoints.
R. Gralla
1:20PM Expert Panel Discussion and Q&A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones, for loss of appetite and weight and also for current and emerging interventions.
Session 3 faculty
SESSION #4: The New Landscape for Squamous Non-Small Cell Lung Cancer Patients
Chair: F. Hirsch
1:30PM DEBATE #3: What should be the standard of care today with FDA-approved agents for Initial therapy for advanced/metastatic squamous NSCLC patients?

Initial therapy of metastatic NSCLC patients with squamous histology and with a good performance status should be:
  • Combination doublet chemotherapy plus an anti-EGFR monoclonal antibody (P. Bunn)
  • Single-agent Immune therapy (H. Wakelee)
P. Bunn versus H. Wakelee
1:50PM What are the clinical applications for chemotherapy for squamous NSCLC patients?
Is there a role for combinations with immune therapy? For combinations with targeted therapy? Is there a role for continuation maintenance chemotherapy?
J. Neal
2:05PM What are the clinical applications of anti-EGFR targeted and anti-VEGFR & therapies for squamous NSCLC? How do they compare with the other FDA approved options?
R. Natale
2:20PM What is the role of immune therapy for squamous NSCLC?How does immune therapy compare with other FDA approved options in the 2nd line setting?
F. Hirsch
2:35PM Expert Panel Discussion, Q&A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones, for Session #4
P. Bunn & Session #4 Faculty
2:45PM BREAK
SESSION #5: The New Landscape for EGFR & ALK-Directed Therapies for NSCLC Patients
Chair: H. Jack West
3:00PM DEBATE #4: A patient has progressed on crizotinib, and then was placed on second-line alectinib, and again subsequently progressed. What next?
  • Use another ALK inhibitor in the third-line setting (Garon)
  • Use chemotherapy, an immune-therapy, or perhaps an experimental agent (Bunn)
E. Garon versus P. Bunn
3:20PM What is the new therapeutic paradigm for using the current and emerging generations of ALK-directed therapies for NSCLC? What factors have impacted sequencing of anti-ALK agents?
P. Bunn
3:40PM Expert Panel Discussion, Q&A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones, regarding EGFR
H. Jack West & Session #5 Faculty
3:50PM DEBATE #5: When a NSCLC patient relapses on initial therapy with an EGFR-directed therapy, and tests negative for T790M Mutation, what should be the subsequent therapy?
  • Immune therapy (Neal)
  • Third-generation EGFR-directed therapy OR Chemotherapy (Wakelee)
J. Neal versus H. Wakelee
4:10PM What is the new therapeutic paradigm for using the three generations of FDA-approved EGFR-directed therapies for NSCLC? What is the impact of new clinical trials data, the T790M Mutation and other EGFR mutation data on therapeutic selection and sequencing?
H. Jack West
4:30PM Expert Panel Discussion, Q&A
The expert panel answers the queued-up questions from the audience submitted via their iPads or other smart devices, and also questions from the floor microphones, regarding ALK
H. Jack West & all Session #5 Faculty
4:50PM CME/CE Post Test
P. Bunn
5:00PM ADJOURN

Overview

Back to Top

CASE-BASED LEARNING
San Francisco Airport Marriott Waterfront Hotel, San Francisco, CA
Saturday, October 15, 2016

This is a one-day CME/CE symposium on the treatment and management of patients with lung cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists and allied healthcare practitioners.

The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, and an essential integration of the many new and emerging therapies into best practices for their lung cancer patients including immune therapy, new and novel targeted therapies, and novel uses of chemotherapy such as maintenance chemotherapy for squamous NSCLC. The target audience includes both academic and community-based lung cancer oncologists, pathologists, radiologists, surgeons, hematologists, fellows, oncology pharmacists, oncology nurses, Nurse Practitioners, physician assistants and other allied healthcare professionals. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.

On behalf of the world-class faculty of expert lung cancer medical oncologists, an Advanced Nurse Practitioner, and a Professor of Pharmacy, we are very pleased to invite you to attend the forthcoming one-day, multi-disciplinary CME/CE program: The 9th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer, Saturday October 15, 2016, at the San Francisco Airport Marriott Waterfront Hotel. This is THE lung cancer symposium to attend in 2016. The October 15th symposium will present practical information that is relevant to lung cancer practices, presented in case-based learning by lung cancer experts. During 8 hours on a Saturday, it will provide the precise summarized information you need to be totally up-to-date on how to treat your lung cancer patients to improve their outcomes.

This year there is significant focus on the integration of Immune therapy and novel targeted therapy into traditional chemotherapy, as well as an update on the status of NGS testing to address NSCLC patients without actionable mutations, including patients with squamous cell carcinoma of the lung. And as always, heavy emphasis is placed in the use of interactive case studies and other learning formats to achieve the highest level of learner/audience interactivity with the faculty and the program.

Participants will enjoy a highly interactive educational program. Real-life patient cases are used throughout the day addressing the application of new clinical strategies with personalized medicine for lung cancer.

Using iPads or other smartdevices provided at the symposium, participants will make patient management and treatment decisions involving clinical cases presented by the expert lung cancer faculty.

Participants will also use iPads to "answer yes or no" to rapid-fire questions on key topics addressing unmet medical needs; to vote on several lively debates addressing new and emerging clinical strategies; and, to take personal notes on the slides of the presentations. Each participant’s notes along with copies of all data presented throughout the day will be emailed to each participant immediately following the symposium.

During the past year a large amount of new information addressing the unmet medical needs of lung cancer patients has been published. This includes novel therapies and new and emerging standards of care. Strategies involving best clinical practices with personalized medicine are the focus of this symposium. And the timing of this program is designed to provide the participants with the most important clinical and scientific data of the year. This material is the most up-to-date possible on lung cancer.

Now in its 9th consecutive year, this symposium on Saturday October 15, 2016 provides a one-day update on the latest developments in the care and management of lung cancer patients. Up to 8.25 hours of CME/CE credit can be earned for participating.

Bring your own Smartphones, Tablets, or Laptops
(iPad, Android, iPhone, etc.): This will enable participants to use their personal "smart devices" during the symposium to ask and answer all questions of the faculty.

 

Educational Need

Back to Top

In 2016, lung cancer is the leading cause of cancer deaths in the US, remains a significant unmet medical need, and, is expected to be a major clinical and scientific challenge for the foreseeable future, but with modest incremental advances. According to the American Cancer Society Facts and Figures there were an estimated 225,000 new cases, and 160,000 deaths from lung cancer this in 2015. Survival rates for patients with lung cancer vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancer are diagnosed at late stages of disease, especially Stages II and mostly IV, the five-year survival rate for Stage IV NSCLC is approximately two percent. Thus, it is clear that there is incredible opportunity for improving outcomes for patients with lung cancer.

Despite the overall poor outcome, lung cancer patient outcomes are improving. Patients are living longer and with a better quality of life because physicians and other healthcare professionals have access to the information to gain the knowledge and competence to treat, care for and manage their patients. Physicians have a better understanding of lung cancer cell biology, an increasing ability to personalize existing and emerging systemic lung cancer drug therapy because of molecular and genomic diagnostic tests, the availability to use next-generation systemic lung cancer therapy and expanded uses of many existing systemic lung cancer drug therapies.


Target Audience

Back to Top

This activity is designed to meet the educational needs of and help close Practice Gaps of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation.

Targeting this audience of clinicians and scientists is intended to help improve the dissemination of the most current and practical educational information of this activity required for closing Practice Gaps and improving the outcomes of NSCLC patients through maximized application of personalized medicine and best clinical practices. With the very rapidly increasing number of new targeted and immune therapies, including anti-VEGF antibodies, new small targeted molecules, and immune checkpoint inhibitors for which most do not yet have validated biomarkers, the term, "best practices" takes on increasing significance.


Faculty Disclosures

Back to Top

Medical Oncology Faculty

Paul A. Bunn, Jr, MD (Co-Chair)
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO

Tracey L. Evans, MD
Associate Professor of Clinical Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA

Edward B. Garon, MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Jonathan Goldman, MD
Associate Professor of Medicine
Lung Cancer Research
Department of Hematology/Oncology
UCLA Ronald Reagan Medical Center
Santa Monica, CA

Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York

Fred R. Hirsch, MD, PhD
Professor of Medicine and Pathology
Pia and Fred R. Hirsch Endowed Chair
Associate Director, University of Colorado Cancer Center
CEO, International Association for the Study of Lung Cancer (IASLC)
Denver, CO

Ronald B. Natale, MD
Director of the Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Joel Neal, MD, PhD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA

David R. Spigel, MD
Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford Comprehensive Cancer Center
Stanford, CA

H. Jack West, MD (Co-Chair)
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education (GRACE)
Seattle, WA

Oncology Nursing Faculty

Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Clinical Instructor in Nursing
Thoracic Oncology Program
Yale Comprehensive Cancer Center
Yale Schools of Nursing and Medicine
New Haven, CT

Oncology Pharmacist Faculty

Jim M. Koeller, MS
Professor,
University of Texas at Austin
College of Pharmacy,
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine, Pharmacotherapy Education & Research
University of Texas Health Science Center at San Antonio
San Antonio, TX

 
BioMedical Learning Institute

LEAD NURSE PLANNER
Diane D. DePew, DSN, RN-BC
I have no real or apparent conflicts of interest to report.

PLANNER & CME/CE REVIEWER
Stephen G. Madison, BSPharm, MBA, CHCP (BMLI Manager)
I have no real or apparent conflicts of interest to report.

CME/CE PEER REVIEWER
Danielle Shafer, MD
I have no real or apparent conflicts of interest to report.

Learning Objectives

Back to Top

Physicians

  1. Compare and contrast the differences between the various approved and emerging immune therapeutic strategies for NSCLC patients in the relapsed and treatment naïve settings.
  2. Analyze the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  3. Devise experimental therapeutic strategies using combination regimens containing an immune oncology therapy plus either another immune therapy, a targeted therapy, or chemotherapy.
  4. Understand how to devise personalized, systemic, NSCLC treatment strategies against otherwise non-actionable targets such as KRAS, MET, MEK, CDK4 and CDK6 based upon the results of Next-Generation Sequencing (NGS) testing.
  5. Compare and contrast the various treatment strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including which, when and how to use liquid biopsies to help guide therapy selections.
  6. Compare and contrast the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  7. Understand the strategies for treating patients in the evolving ALK landscape in NSCLC, including when and how to use second-line therapy for treatment-naïve patients and for managing relapsed patients with CNS involvement.
  8. Compare and contrast the new and emerging value-based care system for reimbursement and payment of anti-cancer therapy versus the fee for service system including the process of transitioning to the new value-based system.
  9. Understand how the new COME HOME project from the Center for Medicare & Medicaid Innovation reduces costs, enhances patient care and improves outcomes for patients with lung cancer.
  10. Describe how initiating the use of appropriate supportive care for lung cancer improves patient outcomes, including overall survival.
  11. Analyze the evidence-based data from major Phase III trials supporting the role of an oral gherlin receptor agonist for the treatment of loss of weight and loss of appetite in patients with advanced NSCLC.

Nurses

  1. Describe the differences between the various approved and emerging immune therapeutic strategies for NSCLC patients in the relapsed and treatment naïve settings.
  2. List the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  3. Recall experimental therapeutic strategies using combination regimens containing an immune oncology therapy plus either another immune therapy, a targeted therapy, or chemotherapy.
  4. Identify the personalized, systemic, NSCLC treatment strategies against otherwise non-actionable targets such as KRAS, MET, MEK, CDK4 and CDK6 based upon the results of Next-Generation Sequencing (NGS) testing.
  5. Define the various treatment strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including which, when and how to use liquid biopsies to help guide therapy selections.
  6. List the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  7. Recall the strategies for treating patients in the evolving ALK landscape in NSCLC, including when and how to use second-line therapy for treatment-naïve patients and for managing relapsed patients with CNS involvement.
  8. Describe the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  9. Recall the current progress in the management of oligometastatic NSCLC.
  10. List the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Identify the evidence-based data from major Phase III trials supporting the role of an oral gherlin receptor agonist for the treatment of loss of weight and loss of appetite in patients with advanced NSCLC.

Pharmacists

  1. Describe the differences between the various approved and emerging immune therapeutic strategies for NSCLC patients in the relapsed and treatment naïve settings.
  2. List the new and existing strategies including immune therapy, novel chemotherapy and targeted therapy for patients with squamous NSCLC across all lines of therapy including the treatment-naïve, relapsed and maintenance settings.
  3. Recall experimental therapeutic strategies using combination regimens containing an immune oncology therapy plus either another immune therapy, a targeted therapy, or chemotherapy.
  4. Identify the personalized, systemic, NSCLC treatment strategies against otherwise non-actionable targets such as KRAS, MET, MEK, CDK4 and CDK6 based upon the results of Next-Generation Sequencing (NGS) testing.
  5. Define the various treatment strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including which, when and how to use liquid biopsies to help guide therapy selections.
  6. List the various strategies targeting EGFR mutations in NSCLC, including monotherapy versus combination therapy and the impact on therapy related to differences in mutations.
  7. Recall the strategies for treating patients in the evolving ALK landscape in NSCLC, including when and how to use second-line therapy for treatment-naïve patients and for managing relapsed patients with CNS involvement.
  8. Describe the pros and cons of using Stereotactic Ablation Body Radiation (SABR) as an equivalent alternative standard of care to surgery for stage I NSCLC patients.
  9. Recall the current progress in the management of oligometastatic NSCLC.
  10. List the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  11. Identify the evidence-based data from major Phase III trials supporting the role of an oral gherlin receptor agonist for the treatment of loss of weight and loss of appetite in patients with advanced NSCLC.

CME/CE Accreditation and Credit Designation

Back to Top

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-16-004-L01-P
Credits: 8.25 hours (0.825 ceu)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.


Location of this Symposium

Back to Top

San Francisco Airport Marriott Waterfront
1800 Old Bayshore Highway
Burlingame, California 94010
Phone: (650) 692-9100

Hotel Sleeping Rooms

The deadline for the $162/night discounted room rate has been extended to Friday, September 30, 2016.

Click here to reserve your room at the discounted rate.


Live Internet Simulcast

Back to Top

Instructions will be emailed the week of the symposium. Kindly check your SPAM folder if you have not received the instructions.


Exhibit Information

Back to Top

There is an opportunity to exhibit at this symposium. Please send an email to exhibits@bmli.com for more information or call 214-269-2014 (All calls will be answered within 24 hours).

EXHIBIT FEES:

  • If your company is a "commercial supporter" for CME/CE of this symposium; $799 for one table; $999 for 2 tables.
  • If your company is not a "commercial supporter" for CME/CE of this symposium $1,499 for one table; $2,499 for 2 tables.
  • If your company is an Advocacy Group, such as Bonnie J. Addario Lung Cancer Foundation, LUNGevity, Free to Breathe, Lung Cancer Alliance, American Lung Association, etc., there is NO fee for Exhibit space.

TERMS FOR EXHIBITORS:

  • Exhibitors who are not registered attendees to the symposium will not have access to the buffet breakfast or the buffet Lunch with the Professors.
  • The Exhibitors will not have access to the scientific sessions unless they are registered for the activity.

Educational Support

Sincere appreciation is extended to companies providing support for this independent educational activity.

Lilly
Helsinn
Celgene
Merck
Astellas
Myriad Genetic Laboratories
Novartis
Table of Contents
Educational Partner